Drug Profile
Research programme: c-Met inhibitors - Eli Lilly and Company
Alternative Names: SGX 126Latest Information Update: 04 Apr 2012
Price :
$50
*
At a glance
- Originator SGX Pharmaceuticals
- Developer Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 31 Dec 2011 No development reported - Preclinical for Solid tumours in USA (Parenteral)
- 24 Oct 2008 Pharmacodynamics and pharmacokinetics data from preclinical trials in Cancer presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
- 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly and Company